Cardiol Therapeutics Inc. Class A · TSX:CRDL
Cardiol Therapeutics Inc. Class A — Investor Presentation (December 2023)
31 slides from Cardiol Therapeutics Inc. Class A's investor presentation, December 2023
Slide 1: Heal the heart with innovative science
Corporate Presentation Heal the heart with innovative science We are a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease Cardiolrx.com TSX: CRDL December 2023 NASDAQ: CRDL
Slide 2: Disclaimer
Disclaimer In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of Cardiol Therapeutics Inc. (“Cardiol”) or any other entity contained in this presentation are inte
Slide 3: Developing Novel Therapeutics for Patients with Heart Diseases
Developing Novel Lead Asset in Clinical Development Broad Exclusivity Protection Therapeutic CardiolRx™, oral drug candidate, in Phase II trials for recurrent pericarditis and acute myocarditis. Comprehensive intellectual property portfolio. Eligible to pursue FDA orphan drug and EMA Approaches for
Slide 4: Product Pipeline
Product Pipeline Drug Pre-Clinical Phase I Phase II Phase III Candidate Developing drug candidates CardiolRx™ that attenuate multiple Recurrent Pericarditis inflammatory signaling pathways, including inhibiting Acute Myocarditis activation of the NLRP3 inflammasome, known to play an important role i
Slide 5: Key Global Research and Clinical Collaborators
Key Global Research and Clinical Collaborators Working together with world-class researchers and clinicians at international centers of excellence and leveraging their expertise in drug development, experimental execution, inflammation and fibrosis, the treatment of cardiovascular diseases, and clin
Slide 6: MAvERIC-Pilot Study
MAvERIC-Pilot Study Phase II study to evaluate the tolerability, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis. NASDAQ: CRDL | TSX: CRDL December 2023 6
Slide 7: Recurrent Pericarditis
Recurrent Pericarditis • Pericarditis refers to inflammation of the pericardium (the membrane, or sac, surrounding the heart) that leads to fluid accumulation (effusion) and pericardial thickening. • Recurrent pericarditis is the reappearance of symptoms after a symptom-free period of at least 4 – 6
Slide 8: Significant Reduction of Multiple in vitro Parameters Demonstrated Pre-clinically
Significant IL-1β Pro IL-1β mRNA Reduction of ***P<0.001 *P<0.05 ***P<0.001 Multiple in vitro Parameters Demonstrated Pre-clinically IL-6 NLRP3 mRNA IL-1β & IL-6 Secretion Inhibited; Transcription Levels of pro-IL-1β ***P<0.001 *P<0.05 ***P<0.001 & NLRP3 Reduced. Martinez-Naya N et al. Circ Res 2022
Slide 9: Significant Reduction in Pericardial Effusion & Pericardial Thickness
Significant Reduction in Pericardial Pericardial Space Pericardial Thickness Zymosan A Effusion & Pericardial Thickness Demonstrated Zymosan A + Cannabidiol 10 mg/kg in vivo Pre-clinically Pericardial thickness of heart sections stained with hematoxylin and eosin. Martinez-Naya N et al. Circ Res 202
Slide 10: Advisors and Key Investigators for the MAvERIC-Pilot Study
Advisors and Key Investigators for the MAvERIC-Pilot Study Allan Klein, MD, CM Paul Cremer, MD Study Chair Departments of Medicine and Radiology, Northwestern University, and Multimodality Cardiac Imaging and Clinical Trials Unit, Bluhm Director, Center for the Diagnosis and Treatment of Pericardial
Slide 11: CardiolRx for Recurrent Pericarditis
CardiolRx™ for Recurrent Pericarditis Phase II MAvERIC-Pilot Study Primary Efficacy Endpoint Multi-center, open-label pilot study to assess the safety and tolerability of CardiolRx™ during the • Change, from baseline to 8 weeks, in patient- resolution of a pericarditis recurrence, evaluate reported
Slide 12: Recurrent Pericarditis: Market Opportunity
Recurrent Pericarditis: Market Current Pharmacotherapy • First-line conventional treatment: NSAIDs or aspirin with or without colchicine(1). Opportunity • Second-line therapy for patients with continued recurrence and inadequate response: corticosteroids (despite safety issues and difficulty taperin
Slide 13: ARCHER Trial
ARCHER Trial Phase II study of CardiolRx™ in patients with acute myocarditis. NASDAQ: CRDL | TSX: CRDL December 2023 13
Slide 14: Acute Myocarditis
Acute Myocarditis • Inflammatory condition of the heart muscle (myocardium) often resulting from viral infection. • Characterized by chest pain, impaired heart function, arrythmias, and conduction disturbances. • An important cause of acute and fulminant heart failure in young adults and a leading c
Slide 15: Cannabidiol Attenuates Myocarditis-induced Fibrosis
Cannabidiol Attenuates Myocarditis-induced Fibrosis Effect of Cannabidiol on Heart Fibrosis Sections of Heart Tissue – Fibrosis Healthy Tissue Myocarditis Myocarditis + Cannabidiol Representative images of Sirius red-stained LV myocardium sections. Magnification: 100x. Lee W-S et al. (2016). Mol. Me
Slide 16: Steering Committee for the ARCHER Trial
Steering Committee for the ARCHER Trial Dennis M. McNamara, MD Leslie T. Cooper, Jr., MD Chair Co-Chair Professor of Medicine at the University of Pittsburgh. He is also the Director of the General cardiologist and the Chair of the Mayo Clinic Enterprise Department of Heart Failure/Transplantation P
Slide 17: CardiolRx for Acute Myocarditis
CardiolRx™ for Acute Myocarditis Phase II ARCHER Trial Multi-national, double-blind, randomized, placebo- controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with Primary Efficacy Endpoints* acute myocardit
Slide 18: Acute Myocarditis: Market Opportunity
Acute Myocarditis: Current Pharmacotherapy • No FDA-approved therapies for acute myocarditis. Market • Management: guideline directed therapy for heart failure and arrythmia (e.g., β-blockers, Opportunity ACE-I, ARBs, inotropes, diuretics). • Goal: decrease cardiac workload, reduce congestion and im
Slide 19: Heart Failure
Heart Failure CRD-38 is a novel proprietary subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. NASDAQ: CRDL | TSX: CRDL December 2023 19
Slide 20: Heart Failure
Heart Failure • A complex clinical syndrome with signs and symptoms that result from any structural or functional impairment of ventricular filling or ejection of blood in the heart. • Patients experience shortness of breath, rapid heart rate, and edema, resulting in reduced exercise capacity, limit
Slide 21: Types of Heart Failure
Types of Heart Failure • Systolic heart failure, also referred to as heart failure with reduced ejection fraction (HFrEF), occurs when the heart loses its ability to contract normally and is unable to pump with sufficient force to push enough blood into circulation. • Diastolic heart failure, also r
Slide 22: Subcutaneous CRD-38 Administered Cannabidiol as a Potential Treatment for HFpEF
Subcutaneous Reduces Body Weight Gain Reduced Visceral to Subcutaneous Fat Ratio CRD-38 Administered Cannabidiol as a Potential Treatment For Prevents Inflammation Prevents Cardiac Remodeling Heart Failure With Preserved Ejection Fraction Lozano O et al. Heart Failure Society of America Annual Scien
Slide 23: Cardioprotective Properties of Subcutaneous Cannabidiol Formulation
Cardioprotective Properties of Subcutaneous Cannabidiol Formulation Demonstrated in a Non-ischemic Model of Heart Failure Measurements of BNP mRNA expression in heart tissue Heart Sections Stained with Masson’s Trichome CONTROL ANGIOTENSIN II 5 *** BNP mRNA BNP/GAPDH 4 (fold change) # 3 2 ANGII + Ca
Slide 24: Cannabidiol Inhibits and Promotes Reversal of Mechanisms leading to Cardiac Fibrosis
Cannabidiol Inhibits and also Promotes Reversal of Mechanisms leading to Cardiac Fibrosis in a Dose Dependent Manner Protects cardiac function and exhibits an anti-fibrotic effect, possibly mediated by endothelial-to-mesenchymal transition (“EndoMT”) Immunoflourescence (IF) images of HUVEC cells Top
Slide 25: Heart Failure: Market Opportunity
Heart Failure: Market Current Pharmacotherapy Opportunity • Treatment goals: improve symptoms, patient clinical status, functional capacity, and quality of life; prevent hospitalizations; reduce mortality. o HFrEF (systolic): guideline directed therapy includes four core medication classes – RAS Unm
Slide 26: Major Milestones
Major Milestones 1 Phase II Recurrent Pericarditis Study 2 Phase II Acute Myocarditis Study 3 Subcutaneous Administered CRD-38 • Interim analysis. • Complete 50% enrollment. • Complete IND-enabling studies. • Complete 100% enrollment. • Complete 100% enrollment. • Submit IND. • Initiate Phase III pr
Slide 27: Management Team
Management Team David Elsley, MBA Andrew Hamer, MBChB President and Chief Executive Officer Chief Medical Officer and Head of Research & Development Founder and former President and CEO of Vasogen Inc. More than 30 years’ Thirty years of global life sciences industry, medical affairs, and cardiology
Slide 28: Board of Directors
Board of Directors Guillermo Torre-Amione, MD, PhD David Elsley, MBA Chairman President and Chief Executive Officer Professor of Cardiology at the Methodist Hospital Research Institute, Professor of Founder and former President and CEO of Vasogen Inc. More than 30 years’ Medicine at the Weill Cornel
Slide 29: Scientific Advisory Board
Scientific Advisory Board Dr. Paul M. Ridker, MD, MPH Dr. Bruce McManus, PhD, MD Dr. Joseph A. Hill, MD, PhD Senior Advisor Senior Advisor Senior Advisor Director of the Center for Cardiovascular Disease Professor Emeritus, Department of Pathology and Professor of Internal Medicine and Molecular Bio
Slide 30: Developing Novel Therapeutics for Patients with Heart Diseases
Developing Novel Lead Asset in Clinical Development Broad Exclusivity Protection Therapeutic CardiolRx™, oral drug candidate, in Phase II trials for recurrent pericarditis and acute myocarditis. Comprehensive intellectual property portfolio. Eligible to pursue FDA orphan drug and EMA Approaches for
Slide 31: Cardiol Therapeutics Inc. contact
Cardiol Therapeutics Inc. +1 289.910.0850 NASDAQ: CRDL Toronto, Cardiolrx.com Investor.relations@cardiolrx.com TSX: CRDL Ontario
Cardiol Therapeutics — Investor Presentation (December 2023) on 6ix